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Cytidine deaminasee primary mechanism by which APOBEC3G restricts HIV-1; however, several
studies have reported that APOBEC3G also inhibits virus replication via a mechanism that is independent of
deamination. Using active site APOBEC3G mutants, we have re-evaluated the biological relevance of
deaminase-independent APOBEC3G-mediated restriction of HIV-1. APOBEC3G proteins with Glu→Ala
mutations in AS1, AS2 or AS1 and AS2 were stably expressed at physiological levels in CEM-SS T cells and
293T cells and the ability of the cells to support Δvif HIV-1 replication was then tested. The AS2 and AS1/AS2
mutants were packaged efﬁciently into virions but in single-cycle or multi-cycle HIV-1 replication assays,
were found to lack antiviral activity. The AS1 mutant, which retained deaminase activity, maintained near
wild-type antiviral function. To determine the potency of APOBEC3G antiviral activity, cell lines were
established that that expressed low levels of wild-type APOBEC3G and generated virions that contained as
few as 1–2 APOBEC3G molecules. Even at very low copy number, APOBEC3G caused a signiﬁcant reduction in
infectivity, suggesting that a single molecule of packaged APOBEC3G inactivates the virus. The high potency
of APOBEC3G is consistent with a catalytic mechanism of restriction in which a single molecule can induce a
string of mutations but difﬁcult to reconcile with a deaminase-independent, non-catalytic mechanism.
Analysis of the reverse transcript sequences showed that the G→A mutations were clustered, likely reﬂecting
the action of single APOBEC3G molecules acting processively. We conclude that cytidine deamination is the
mechanism by which APOBEC3G restricts HIV-1.
© 2009 Elsevier Inc. All rights reserved.IntroductionAPOBEC3 cytidine deaminases constitute a critical arm of the
innate immune system that potently restricts retrovirus replication
(Harris and Liddament, 2004). HIV-1 escapes APOBEC3G-mediated
restriction by encoding Vif, an accessory protein that induces the
degradation of APOBEC3G through a proteasome dependent pathway
(Kao et al., 2003; Mariani et al., 2003; Marin et al., 2003; Mehle et al.,
2004; Sheehy, Gaddis, and Malim, 2003; Stopak et al., 2003; Yu et al.,
2003). Δvif HIV-1 cannot replicate in primary T cells and macrophages
but, in laboratory cell lines such as HeLa, human embryonic kidney
293T or CEM-SS that do not express APOBEC3G, the virus replicates
with wild-type kinetics. In cells infected with Δvif HIV-1, APOBEC3G
molecules are packaged into virions as they assemble at the plasma
membrane (Alce and Popik, 2004; Khan et al., 2005; Schafer, Bogerd,
and Cullen, 2004; Zennou et al., 2004). In the next round of virus
replication, the packaged APOBEC3G deaminates the minus-strand
reverse transcript as it is synthesized from the plus-stranded genomic
RNA template (Harris et al., 2003; Mariani et al., 2003; Zhang et al.,
2003). Δvif virions produce a reduced number of full-length reverse. Landau).
ll rights reserved.transcripts, either as a result of degradation of the uracil-containing
cDNA or effects of APOBEC3G on reverse transcriptase-mediated
synthesis (Bishop, Holmes, andMalim, 2006; Guo et al., 2007; Iwatani
et al., 2007; Yang et al., 2007).
The APOBEC3G protein contains two cytidine deaminase domains,
each of which harbors an active site containing a conserved Cys/His-
Xaa-Glu-Xaa23–28-Pro-Cys-Xaa2–4-Cys motif. In this motif, the Cys/His
residues coordinate a Zn2+ ion and the glutamic acid acts as proton
shuttle in catalysis (Carlow, Short, and Wolfenden, 1996). Mutation of
the active site 2 (AS2) glutamic acid residue (Glu259) abolishes
catalytic activity (Navarro et al., 2005; Newman et al., 2005) while
mutation of this residue in active site 1 (AS1)(Glu67) has little effect.
This ﬁnding demonstrated that catalysis is mediated by AS2. In some
reports, Glu259-mutated APOBEC3G was found to have little or no
antiviral activity (Navarro et al., 2005). This ﬁnding led to the
conclusion that that cytidine deamination is required for virus
restriction. Mutation of Glu67 in AS1 does not affect APOBEC3G-
mediated antiviral activity, but mutation of the Cys/His Zn2+
coordination residues reduces virion packaging of the enzyme and
thus prevents antiviral activity (Navarro et al., 2005; Newman et al.,
2005). Further support for the requirement for deaminase activity was
provided by an analysis of mouse Apobec3. The mouse genome
encodes a single Apobec3 protein in which the roles of the two
cytidine deaminase domains are reversed, such that AS1 mediates the
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Landau, 2006). In themouse protein, the AS1, but not the AS2 glutamic
acid residue was required for antiviral activity. Taken together, these
ﬁndings supported the conclusion that the principal mechanism by
which APOBEC3G restricts HIV-1 is cytidine deamination.
In spite of these ﬁndings, there is evidence that APOBEC3G can also
restrict HIV-1 by a deaminase-independent mechanism. Newman et al.
reported that APOBEC3G with a Glu259Gln mutation of AS2 lacked
cytidine deaminase activity yet maintained potent antiviral activity
(Newman et al., 2005). In resting primary T cells, APOBEC3Gwas found
to restrict HIV-1 in the target cell, and themajority of newly synthesized
reverse transcripts lacked G→A hypermutation (Chiu et al., 2005).
APOBEC3G was also found to restrict Hepatitis B virus in the absence of
G→A hypermutation (Turelli et al., 2004). Another APOBEC3 deami-
nase, APOBEC3A, was found to restrict LTR and non-LTR retrotranspo-
sons and adeno-associated virus in the absence of detectable G→A
hypermutation (Bogerd et al., 2006; Chen et al., 2006).
While cytidine deamination is clearly an important mechanism by
which APOBEC3G restricts HIV-1, whether a cytidine deaminase-
independent mechanism plays a signiﬁcant role remains unresolved.
The notion of deaminase-independent restriction of HIV-1 by
APOBEC3G was challenged in the recent reports of Schumacher et
al. (2008) and Miyagi et al. (2007). who found that deaminase-Fig. 1.Wild-type APOBEC3G and active site mutant expression in CEM-SS and 293T stable ce
encode wild-type APOBEC3G (WT), AS1 (E67A), AS2 (E259A) or AS1/AS2 (E67A/E259A) m
APOBEC3G expression levels were determined on an immunoblot probed with anti-APOBE
grouped as “intermediate” and “high” based on APOBEC3G expression level. (B) The EGFP ﬂu
were analyzed for CD4 and CXCR4 expression by ﬂow cytometry. (C) APOBEC3G expressio
isolated from three healthy donors on an immunoblot probed with anti-APOBEC3G serum. (D
immunoblot standardized with recombinant APOBEC3G (left panel). To determine the c
corresponding to a known cell number was analyzed. The amount of APOBEC3G per cell wdeﬁcient APOBEC3G mutants had reduced or undetectable antiviral
activity. To further address this question, we generated transformed T
cell and 293T cell lines that stably expressed wild-type or active site
mutants of APOBEC3G at levels comparable to that of primary T cells,
and tested their ability to restrict replication-competent and single-
cycle Δvif NL4-3. The AS2 deaminase-deﬁcient mutants failed to
restrict Δvif NL4-3 in either assay. In addition, APOBEC3G restricted
Δvif NL4-3 when present in virions that contained as few as 1–2
molecules, a ﬁnding that consistent with an enzymatic mechanism of
restriction. For viruses that contained limited amounts of APOBEC3G,
the G→A mutations occurred in local clusters, consistent with a
processive mechanism of deamination. We conclude that cytidine
deaminase-independent effects of APOBEC3G are likely not to play a
biologically relevant role in HIV-1 restriction.
Results
Generation of stable cell lines that express physiological levels of
wild-type and deaminase-deﬁcient APOBEC3G
Most studies that have detected deaminase-independent antiviral
activity of APOBEC3G have used virions that were generated by the
transient transfection of 293T cells with Δvif NL4-3 proviral DNA andll lines. 293T cells and CEM-SS cells were transduced with pMIGR retroviral vectors that
utants and contain a downstream IRES-EGFP. (A) Cell clones were isolated and their
C3G and anti-tubulin serum. H9 cells were used for comparison. The cell clones were
orescence of the 293T and CEM-SS cell clones was measured, and the CEM-SS cell clones
n in the intermediate CEM-SS clones was compared to primary activated CD4+ T cells
) The copy number of APOBEC3Gmolecules in human T cell lines was determined on an
opy number of APOBEC3G per cell, lysates containing a ﬁxed mass of protein and
as then calculated, standardized to the recombinant APOBEC3G control (right panel).
Fig. 2. An AS2 cytidine deaminase mutant does not inhibit Δvif NL4-3 virion infectivity
in a single-cycle infection. (A) 293T cell clones expressing intermediate levels of
APOBEC3Gwere transfectedwithΔvifNL4-3 and VSV-G plasmids. After 48 h, the virions
were pelleted by ultracentrifugation. APOBEC3G and p24 content of the virions was
visualized on an immunoblot probed with antiserum speciﬁc for these proteins. (B)
293T clones expressing intermediate (upper panel) or high levels (lower panel) of
APOBEC3G were transfected with wild-type or Δvif pNL-Luc and pVSV-G to generate
single-cycle virus. The infectivity of the virus, normalized for p24, was determined by
infection in triplicate of HOS cells. The cells were lysed after three days and luciferase
activity was measured. The results are presented as the luciferase activity of the Δvif
NL4-3 divided by wild-type, and is the average of triplicates.
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expressed from a chromosomal gene and the virus is produced
from an integrated provirus by infected T cells and macrophages. To
study APOBEC3G restriction under conditions that are closer to those
that pertain in vivo, we used the retroviral vector pMIGR, which has
an IRES-EGFP, to construct expression vectors for wild-type (WT),
AS1 (Glu67Ala), AS2 (Glu259Ala) or AS1 and AS2 (Glu67Ala,
Glu259Ala) APOBEC3G. We transduced CEM-SS T cells and 293T
cells, neither of which expresses endogenous APOBEC3G, with
retroviral expression vector to generate cell lines that stably
expressed the enzyme at levels similar to that of primary activated
CD4+ T cells. The transduced cells were cloned by limiting dilution
and their APOBEC3G expression level was determined on an
immunoblot (Fig. 1A). The H9 T cell line was used for comparison
as these cells express a level of APOBEC3G that is similar to that of
primary activated CD4+ T cells (Fig. 1C). Two panels of CEM-SS and
293T cell clones were assembled, one termed “intermediate ” and a
second termed “high” based on their APOBEC3G expression relative
to H9. We were not able to generate a CEM-SS high clone for the AS2
single mutant. The clonality of the cell lines was conﬁrmed by
analysis of EGFP ﬂuorescence which showed a single sharp peak by
ﬂow cytometry (Fig. 1B). Equivalent levels of surface CD4 and CXCR4
were conﬁrmed on the CEM-SS cell lines (Fig. 1B).
To determine whether the expression levels of APOBEC3G in the
CEM-SS clones were similar to that of primary activated CD4+ T cells,
we compared them to cell lysates from three healthy donors on an
immunoblot (Fig. 1C). The level of APOBEC3G in the intermediate cell
lines was somewhat lower than primary T cells but higher than that
of CEM, a Δvif HIV-1 non-permissive T cell line. Using recombinant
APOBEC3G as a standard and cell lysate derived from a known
number of cells (Fig. 1D left panel), we calculated the APOBEC3G
copy number per cell (Fig. 1D, right panel). Primary CD4+ T cells
contained about 30,000 molecules per cell, while H9 cells, which are
larger, contained 100,000 and CEM contained 20,000. Thus, the
amount of APOBEC3G expressed by H9 and primary T cells is well
above what is required to block virus replication. We conclude that
the CEM-SS cell lines expressed APOBEC3G at levels comparable to
H9 and primary T cells and that this amount is more than sufﬁcient
to detect antiviral activity.
Stably expressed deaminase-deﬁcient APOBEC3G lacks detectable
antiviral activity in single-cycle and multi-cycle replication
To determine whether the mutant APOBEC3G proteins could be
efﬁciently packaged into HIV-virions, we transfected the panel of 293T
cell lines with Δvif NL4-3 plasmid, and after two days, harvested the
virus-containing supernatant. An analysis of the APOBEC3G content of
the pelleted virions on an immunoblot showed that the wild-type
APOBEC3G and active site mutants were packaged at similar levels
(Fig. 2A). This result suggests that the mutants were properly folded
and packaged into virions at levels sufﬁcient to mediate deaminase-
dependent and independent activities.
In a previous study, we reported that deaminase-deﬁcient
APOBEC3G mutants packaged in virions produced by transient
transfection of 293T cells caused a 50% reduction in infectivity
(Navarro et al., 2005), a result that could have suggested deami-
nase-independent restriction. To determine whether this effect was
also present when the APOBEC3G mutants were stably expressed, we
transfected the 293T stable cell lines with wild-type or Δvif NL4-3
luciferase reporter virus plasmid and VSV-G expression vector. The
resulting virions were normalized for p24 and tested for infectivity by
infection of target cells. The results showed that the AS1 mutant
maintained its antiviral activity but that the AS2 and AS1/AS2
APOBEC3G mutants caused no detectable reduction of infectivity
(Fig. 2B, upper panel). Similar results were found using the 293T cells
that over-expressed the wild-type and mutant APOBEC3G proteins(Fig. 2B, lower panel). These results suggested that the modest effect
of transiently expressed deaminase-deﬁcient APOBEC3G disappears
when it is expressed stably from an integrated cassette.
We next tested the effect of the APOBEC3G mutants on HIV-1
replication kinetics, a setting in which multiple rounds of virus
replication ampliﬁes modest antiviral effects. For the analysis, the
CEM-SS clonal cell lines were infected with wild-type or Δvif NL4-3
and supernatant p24 was measured over two weeks. Comparison of
wild-type and Δvif virus served to control for possible clone-to-clone
differences in virus replication unrelated to APOBEC3G. The results
showed that the empty vector control cell clones supported similar
levels of wild-type and mutant virus replication, peaking on day eight
(Fig. 3). Wild-type APOBEC3G blocked the replication of Δvif NL4-3
and had a small effect on wild-type virus replication, delaying peak
Fig. 3. An APOBEC3GAS2mutant does not inhibit ΔvifNL4-3 replication in T cells. CEM-SS cell clones that express intermediate or high levels of wild-type APOBEC3G (WT), AS1, AS2,
or AS1/AS2 mutants were infected with wild-type or Δvif NL4-3. The culture medium was sampled every other day for two weeks and p24 was quantitated by ELISA.
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This delay indicates that APOBEC3G can apply pressure to HIV-1 even
when Vif is produced by the virus and suggests that its levels are a
limiting factor for HIV-1 replication in cells that produce physiological
levels of APOBEC3G. At an intermediate level of expression, the AS1
mutant delayed but did not completely block Δvif NL4-3 replication.
When expressed at higher level, this mutant blocked Δvif NL4-3
replication. In contrast, Δvif NL4-3 replicated with wild-type kinetics
in cells that expressed the AS2 or AS1/2 mutants. When expressed at
higher levels the AS1/2 mutant also lacked detectable activity. Taken
together, these results demonstrate that deaminase-deﬁcient APO-
BEC3G lacks antiviral activity when expressed within physiological
levels in T cells.
Restriction of HIV-1 requires only a small number of packaged
APOBEC3G molecules
To determine the potency of the APOBEC3G restriction, we used
293T cell clones that expressed low levels of APOBEC3G. Five clones
were chosen that expressed graded levels of wild-type APOBEC3G,
fromapproximately 5% to 46%of the amount expressed byH9 (Fig. 4A).
To determine the potency of APOBEC3G,we generated virions from the
293Tcell lines by infectionwithΔvifNL4-3(VSV-G) and thenmeasured
their APOBEC3G content (Figs. 4A and B) and corresponding level ofrestriction (Fig. 4C). The two lowest expressing clones, 4 and 5,
produced virions that contained 1.3 and 1.4 APOBEC3G molecules per
virionwhile clones 6 and 8 produced virions that contained 17 and 22
molecules, respectively. The amount of APOBEC3G in the virions
paralleled the amount present in the cell lysates. To determine
infectivity, the virions were titered on GHOST cells. These cells contain
an LTR-EGFP cassette that is transactivated by Tat upon infection. The
titer of viruses produced by clones 4 and 5 were reduced by 20% and
40%, respectively (Fig. 4C). Expression of larger amounts of APOBEC3G
in clone 8 reduced the titer by 95%. The results demonstrated that only
a few, andpossibly one packagedAPOBEC3Gmolecule, can inhibit HIV-
1 virion infectivity.
Antiviral activity correlates with G→A mutational frequency
To determine whether APOBEC3G antiviral activity was correlated
with G→A mutations in the cDNA, we determined the frequency of
G→A mutations in the viral cDNA produced by virions containing
limiting amounts of APOBEC3G. To do this, we infected HOS cells with
viral supernatants derived from Δvif NL4-3 infected 293T cell lines
used in Fig. 4. At 24 h post-infection, we isolated cellular DNA from the
HOS cells and PCR ampliﬁed a 700 base pair fragment of env. We
determined the nucleotide sequence of 11–15 cloned fragments
derived from each cell line. To analyze the sequences, we calculated
Fig. 4.Quantitation of the number of APOBEC3Gmolecules per virion required to inhibitΔvifNL4-3 infectivity. (A) 293Tclones expressing a range of wild-type APOBEC3G levels were
infected with NL4-3 (VSV-G) or Δvif NL4-3 (VSV-G) at an MOI of 0.5. At 72 h post-infection, culture supernatants were harvested and cell lysates were prepared. Virions were
prepared from a portion of the supernatant and the remainder was used to quantitate p24 and determine virus titer. The cell lysates and virions were analyzed on an immunoblot
probed with anti-APOBEC3G and anti-capsid. A serial dilution of recombinant APOBEC3G was included to determine copy number. Mock virions prepared from uninfected clone 8
cells had no detectable APOBEC3G. (B) To determine the number of APOBEC3G copies per virion, the number of APOBEC3Gmolecules per ng of p24was determined by standardizing
the intensity of the virion APOBEC3G band against the recombinant APOBEC3G serial dilution curve for a ﬁxed mass of p24. The number of virions corresponding to 1 ng of p24 was
calculated assuming 2000 copies/virion (Briggs et al., 2004). (C) Virus infectivity was determined by single round infection of GHOST-X4R5 cells. The infectivity of virus produced by
the 239T cell clones is shown as determined by the Δvif NL4-3 infectivity normalized to wild-type. The results are the average of triplicate measurements.
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panel) and the average number of G→A mutations per kilobase (Fig.
5A right panel). Virions from clone 5 generated cDNAs in which 38%
had at least one mutation and with an average of 2.3 mutations per
kilobase, while clone 8 virions generated cDNAs that were nearly all
mutant and had 5.6 mutations per kilobase. A plot of the reduction in
titer against the number of mutations generated shows a linear
relationship (Fig. 5B). A mutation frequency of 3.2 per kilobase
reduced infectivity by 50%. Three mutations per kilobase correspond
to about 30 per genome (not accounting for variation in the
mutational frequency over the genome). Infectivity was determined
using GHOST indicator cells that contain a transactivated LTR-GFP, and
for a cell to score as infected in this assay, it needs only to harbor a
provirus that expresses a functional Tat. Thus, viruses with G→A
mutations in the structural genes will not be detected by the assay. It
was unexpected that a such low mutational frequency would have a
signiﬁcant impact on infectivity. This ﬁnding suggests that it is not the
changes in nucleotide coding capacity that caused the reduction in
infectivity but rather a direct effect on the reverse transcript caused
either by its degradation or a reduction in elongation of the viral
cDNA.
Deamination of the minus-strand reverse transcript is processive over a
short distance
APOBEC3G could deaminate viral DNA distributively, catalyzing a
single mutation and then disengaging from the DNA, or processively,
by sliding along the DNA generating a string of mutations. Support for
both models has been derived using puriﬁed enzyme in vitro onoligonucleotide substrate (Chelico et al., 2006; Coker and Petersen-
Mahrt, 2007; Nowarski et al., 2008; Pham, Chelico, and Goodman,
2007). An analysis of the mutational patterns of the cDNA derived
from the 293T clones allowed us to address this question in the
context of the virion rather than model substrates. In virions that
contained low levels of APOBEC3G, clustered stretches of mutated
sequence are likely to have been generated by the action of a single
molecule. The 700 bp region that we sequenced contained 28
APOBEC3G target sites as deﬁned by bases that had been mutated
more than once in the data set (Fig. 6A). As a measure of processivity,
we calculated pair-wise values for the frequency with which a
mutation at one site was accompanied by mutation at neighboring
sites. The frequency of mutation at a second site will also be affected
by the number of APOBEC3G molecules in the virion, but if
deamination is distributive, this effect should apply equally to all
other target sites of equivalent susceptibility. Processive deamination,
by constrast, predicts that the frequency of mutation at a nearby
second site will be affected more than a distant site with similar
overall mutation frequency. The analysis showed that second site
mutations at nearby target sites had a higher frequency than
expected for independently occurring mutations (Fig. 6B right
panel), consistent with processive deamination. The probability of
two target sites being mutated in the same cDNA was lower for more
distant pairs of sites. The statistical signiﬁcance of this ﬁnding was
demonstrated by a chi-squared test of independence for each pair-
wise relationship (Fig. 6C). Interestingly, the increased frequency of
paired mutations fell into two distinct clusters. A mutation at one
base within a cluster was accompanied by an increased probability of
a second mutation within that cluster but was not associated with an
Fig. 6. APOBEC3G deaminates Δvif NL4-3 in local clusters. APOBEC3G target sites in clones of the 700 bp env fragment generated in cells infected with the 293T cell line-derived
virions were identiﬁed. Patterns of mutation in 55 clones were analyzed using Matlab software (Mathworks). (A) The location of each target site and frequency with which it was
mutated is plotted. (B) The expected coincident frequency of a G→Amutation at a base (Target site B) when one site is mutated (Target site A) if all mutations occur independently is
shown in the left panel. The actual coincident mutational frequency from the dataset is shownwith values that range from no coincidence (dark blue) to 100% coincidence (red) in
the right panel. (C) The statistical signiﬁcance of the difference between the actual and expected values was calculated as P values using a chi-squared test of independence and
plotted (left panel). Pairs of target sites with P values of less than 0.15 and 0.05 are highlighted with blue squares (middle and right panels).
Fig. 5. The antiviral activity of APOBEC3G correlates with frequency of G→A mutation. The 293T cell clones were infected with wild-type or Δvif NL4-3 (VSV-G), and viral
supernatants harvested at 48 h post-infection. The supernatants were then used to infect HOS cells and after 24 h of infection, cellular DNA was isolated. The DNA was used as a
template for PCR ampliﬁcation of a 700 bp fragment of env and the products were cloned into pCDNA3. The nucleotide sequence of 11–15 clones from each infectionwas determined.
(A) The proportion of inserts containing G→A mutations (left panel) and the average number of G→A mutations per kilobase are shown (right panel). (B) The percent inhibition
mediated by APOBEC3G in each of the 293T cell lines as shown in Fig. 4C was plotted against the frequency of G→A changes in the viral DNA as shown in the panel above on the right.
The individual cell clone number is shown above each data point.
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319E.P. Browne et al. / Virology 387 (2009) 313–321increased likelihood of a mutation in the other cluster. The clustering
of mutations suggests processive deamination occurs in local
domains but that there are boundary sequences over which the
enzyme is less likely to cross.
Discussion
We report here, that under conditions that resemble those that
occur in vivo, APOBEC3G restriction of HIV-1 is cytidine deaminase-
dependent. We based this conclusion on the ﬁnding that an APOBEC3G
AS2mutant and an AS1/AS2 double mutant that were stably expressed
at levels similar to that of primary CD4+ T cells, lacked detectable
antiviral activity in single-cycle and multi-cycle replication assays. Our
ﬁndings are consistent with those of Schumacher et al. (2008) who
reported that a CEM-SS APOBEC3G Glu259Gln stable cell line did not
restrict HIV-1 replication, and with Miyagi et al. (2007) who found that
an APOBEC3G AS2 mutant expressed stably in a HeLa cell line had only
minimal effect on infection.
APOBEC3G has been reported to interfere with various steps in
HIV-1 reverse transcription, including initiation and elongation, tRNA
priming and ﬁrst strand transfer (Bishop, Holmes, and Malim, 2006;
Guo et al., 2007; Iwatani et al., 2007; Li et al., 2007). These ﬁndings are
not inconsistent with the conclusion that restriction is caused by
deamination. It is possible that deamination of the reverse transcript
during synthesis could interfere with elongation, strand transfer or
tRNA priming. However, these effects have generally been detected in
with virions generated by transiently expressed APOBEC3G, a method
that can cause an artifactual reduction in virion infectivity. Deami-
nase-deﬁcient APOBEC3G expressed by transient transfection caused
a two-fold reduction in virus infectivity (Navarro et al., 2005) but this
antiviral activity was absent when the APOBEC3G mutants were
expressed stably by an integrated retroviral vector. The reason for the
difference is not clear, but could potentially be caused by the wide
range of expression level per cell in transient transfection as compared
to the relatively constant level in stably transduced cell clones. Further
experimentation will be required to determine whether the effects of
deaminase-deﬁcient APOBEC3G on the various steps in viral genome
replication are active in viruses produced by methods other than
transient transfection.
Our results differ from those of Newman et al. (2005) who found
that an AS2 (Glu259Gln) APOBEC3G mutant retained most of its
antiviral activity and those of Bishop et al. (2006) who found that
antiviral activity did not correlate with the mutational frequency
induced by APOBEC3G/APOBEC3F chimeras. The cause of the different
results is not clear. Our AS2 mutant had a Glu→Ala rather than
Glu→Gln substitution. It is possible that, as shown previously, the AS2
glutamic acid to glutamine mutant retains residual catalytic activity
sufﬁcient to restrict the virus but does not induce enough G→A
mutations to readily detectable by sequencing (Shindo et al., 2003). In
addition, as noted above, we expressed the APOBEC3Gmutants stably,
rather than transiently.
Δvif virions produced by cells that expressed near physiological
levels of APOBEC3G contained on average 17–22 molecules of
APOBEC3G, close to the seven copies found in virions produced by
activated peripheral blood mononuclear cells (Xu et al., 2007). When
the virions were produced by cells that expressed low levels of
APOBEC3G, they contained 1.3 molecules per virion and this resulted
in a 20% reduction in infectivity. Assuming that APOBEC3G is a dimer
(Miller, Presnyak, and Smith, 2007), a Poisson distribution predicts
that 52% of the virions contained no APOBEC3Gwhile 33% contain one
dimer. Thus, a single dimer typically renders the virus noninfectious.
This highly potent activity is consistent with an enzymatic reaction
such as deamination, that can be mediated by a single molecule acting
catalytically, rather than a mechanism such as occlusion of virion
components from the reverse transcription complex or physical
interference with progression of reverse transcriptase.The frequency of APOBEC3G-generated mutations correlated
inversely with infectivity, and a relatively small number of mutations
had an unexpectedly large impact on infectivity. A mutational
frequency of three/kilobase, corresponding to about 30 per viral
genome, reduced virus titers by 50% on GHOST cells, that require only
Tat expression from the provirus to score as infected. If inhibition of
HIV-1 by APOBEC3G occurs primarily via the generation of inactivat-
ing mutations in essential coding proteins or controlling regions, only
rare mutations in Tat itself or the LTR promoter will affect the titer as
determined by this method. Thus, most of the effect on infectivity was
likely due to a direct effect of deamination on the reverse transcript,
probably caused either by interference with elongation of the reverse
transcript or degradation by repair enzymes. Consistent with this
conclusion, Bishop et al. recently reported that APOBEC3G causes
reverse transcriptase to disengage from minus-strand synthesis with
increasing distance from the initiation site (Bishop et al., 2008).
Using model oligonucleotide substrates, APOBEC3G-mediated
deamination has been found to be either processive or distributive
(Chelico et al., 2006; Coker and Petersen-Mahrt, 2007; Pham, Chelico,
and Goodman, 2007). In our study we were able to address the
question of processivity as it occurs in the reverse transcription
complex of a newly infected cell. For this, we analyzed the clustering
of mutations in the cDNA generated by viruses that contained limited
numbers of APOBEC3G molecules. In viruses that contain one or a
small number of APOBEC3G molecules, mutations were rare, but
occurred in patches, presumably the result of a single APOBEC3G
molecule acting processively. An analysis of the clustering of the
mutations showed that the enzyme acts on discrete domains of the
reverse transcript that are ﬂanked by regions of sequence that cause
the enzyme to disengage. These boundaries could be caused by
unfavorable nucleotide sequences or by a tendency for RNAse-H to
leave stretches of double stranded sequence that would be protected
from deamination.
Our conclusion that APOBEC3G-mediated restriction is caused by
cytidine deamination does not extend to other systems in which
APOBEC3 family members are active. Restriction of HTLV-1 by
APOBEC3G was found to occur in the absence of hypermutation
(Sasada et al., 2005). Mouse mammary tumor virus and murine
leukemia virus were found to be suppressed by murine Apobec3 in the
absence of hypermutation (Browne and Littman, 2008; Okeoma et al.,
2007; Rulli et al., 2008). In cell culture, adeno-associated virus was
restricted by APOBEC3A without hypermutation and a catalytically
inactive mutant APOBEC3A maintained its antiviral activity (unpub-
lished observation). In addition, APOBEC3A was active against
endogenous retroelements without causing hypermutation (Bogerd et
al., 2006).
The critical role of cytidine deamination in the restriction of HIV-1
provides a rationale for the evolutionary conservationAPOBEC3 catalytic
activity. The catalyticmechanismprovides ameans bywhich a relatively
small number of packagedmolecules can inﬂict considerable damage to
the viral genome. The mechanism by which APOBEC3 proteins restrict
the replication of other viruses still needs to be addressed.
Materials and methods
Cell lines and primary cells
H9 and CEM-SS cells were cultured in RPMI 1640 medium
supplemented with 10% FBS. HEK 293T, HOS human osteosarcoma
and GHOST-X4R5 reporter cells were cultured in Dulbecco's modiﬁed
Eagle's medium supplemented with 10% fetal bovine serum. pMIGR.
APOBEC3G retroviral vector stocks were prepared by calcium phos-
phate transfection of 293T cells. The pMIGR plasmid was originally
constructed byWarren Pear (University of Pennsylvania). CEM-SS and
293T cells were infected with 1.0 ml of virus-containing supernatant.
After ﬁve days, the cells were sorted by FACS for EGFP expressed from
320 E.P. Browne et al. / Virology 387 (2009) 313–321the pMIGR IRES-EGFP cassette. Single cell clones were generated by
limiting dilution for CEM-SS and by isolation of single colonies for
293T. Primary CD4+ T cells were obtained from anonymous healthy
donor peripheral blood mononuclear cells that were positively
selected on magnetic anti-CD4-coated beads and then activated with
anti-CD28/CD3 coated beads. The resulting cells were N95% CD45RO+.
Protein lysates were harvested at 8 days post activation.
Western blots
Cells in a conﬂuent 6-well plate werewashedwith PBS and lysed in
buffer containing 150 μl of lysis buffer (10 mM TRIS, pH 7.5; 1.5 M
NaCl; 2mMEDTA; 0.5% v/v NP-40) for 30min at 4 °C. The lysateswere
cleared by centrifugation for 10 min at 14,000 ×g at 4 °C. The lysate
was mixed with reducing sample buffer, heated for 7 min at 95 °C and
an amount corresponding to 20 μg of protein was subjected to SDS-
PAGE on a 4–12% gradient gel. Baculovirus expressed recombinant
human APOBEC3G (Immunodiagnostics Inc.) was run in parallel to
determine copy number. To isolate virion proteins, virus-containing
supernatants were clariﬁed by centrifugation at 2000 rpm for 5 min,
ﬁltered through a 0.45 μM ﬁlter and then pelleted by ultracentrifuga-
tion through a 1.0 ml 20% sucrose cushion for 90 min at 25,000 rpm in
an SW41 rotor. The pellet was resuspended in PBS, dissolved in
loading buffer and the proteins were separated by SDS-PAGE. The gel
was transferred to a nitrocellulose membrane and probed with rabbit
anti-APOBEC3G serum (provided by W. Greene, University of
California, San Francisco) or mouse anti-tubulin monoclonal antibody
and then hybridized with biotinylated goat anti-rabbit or goat anti-
mouse secondary antibody. The ﬁlter was developed by incubation
with Streptavidin DayLight 680 conjugate and quantitated on an
Odyssey Infrared Imaging System at 700 nm.
Sequence analysis of reverse transcripts
HOS cells were infected with DNAse-I treated virus-containing
supernatant (50 ng of p24) for 2 h. The virus was removed by three
washes in PBS. After 24 h, the cells were lysed in digestion buffer
(100 mM NaCl, 10 mM Tris pH 8, 25 mM EDTA, 0.5% SDS, 0.1 mg/ml
proteinase K). The lysate was incubated overnight at 50 °C and the
cellular DNA was ethanol precipitated and resuspended in ddH20
overnight at 50 °C. Viral DNA sequences were ampliﬁed from 1 μl of
cellular DNA template with primers complementary to env that
contained terminal EcoRI sites (forward primer: TGTGTGGAATTCTCAG-
CACTTGTGGAGATGGG and reverse primer: TGTGTGGAATTCGACATTTG-
TACATGGTCCTG). The PCR products were cloned into pCDNA3 at the
EcoRI site.
Single-cycle infection
For data shown in Fig. 2, reporter virus stocks were generated by
transfection of 293Tcells using calcium phosphatewith pNL.Luc.R−E−
(Connor et al., 1995) or pNL.Luc.R−E−V− that contains a ﬁreﬂy
luciferase gene in place of nef. 293T cells were seeded at 4.0×105
cells/well in a 6-well plate and the next day transfected with 5 μg
reporter virus plasmid and 1.5 μg of pcVSVG. Two days later, the
supernatant was harvested, centrifuged for 5 min at 400 ×g, ﬁltered
through a 0.45-μm ﬁlter and frozen at −80 °C in aliquots. p24 in the
supernatant was quantitated by ELISA. To determine the infectivity of
the virus, HOS.T4.X4 cells were seeded in a 96-well plate at 1.0×104
per well and the next day infected in triplicate with virus-containing
supernatant (0.25 ng p24). After three days, luciferase activity was
measured using Steady Lite HTS (PerkinElmer Life Sciences). For data
shown in Fig. 4, 293T clones were infected with 50 ng of NL4-3 or
ΔvifNL4-3 that had been pseudotyped with VSV-G. At 48 h post-
infection, viral supernatants were harvested, quantitated for p24
levels, and used to infect GHOST X4R5 cells (2.5×104) that wereseeded in a 12-well plate. After two days, EGFP expression was
evaluated by ﬂow cytometry.
HIV-1 replication kinetics
Replication-competent NL4-3 and Δvif NL4-3 stocks were pro-
duced by transfection of 293T cells, quantitated and frozen in aliquots.
CEM-SS cell clones (1×105) were infected with 40 ng of wild-type or
Δvif NL4-3 corresponding to an MOI of 0.05 in a 12 well dish. To
facilitate infection, the cells were centrifuged for 2 h at 400 ×g. After
24 h, the input virus was removed with by washing twice with PBS.
The culturemediumwas sampled every other day over twoweeks and
p24 was quantitated.
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